Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). |
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
5D3XZhWd4pkD3MDd
